glp-1 supply shortage news november 2025 = Over GLP-1 Nutritional Support Market Size

Despite this, fewer than 1 in 5 employers with over 200 employees currently cover GLP1s for weight loss purposes, even as employee interest continues to climb steadily

Novo Nordisk takes PADE reporting requirements seriously and we plan to address the requests in the Warning Letter expeditiously and holistically, the statement read, referring to safety reports sent to the FDA after a drug's approval.

Mojsov, S., Weir, G

WHAT HAPPENS WHEN YOU STOP

Hopefully, these potential adverse effects observed in animal studies will be addressed in clinical trials of these new, higher-dose oral GLP-1 drugs using SNAC before their widespread introduction